中国肿瘤生物治疗杂志2018，Vol.25Issue(10)：967-978,12.DOI:10.3872/j.issn.1007-385x.2018.10.001
结直肠癌免疫治疗的现状、挑战和出路
Immunotherapy for colorectal cancer:current status, challenges and solution
摘要
Abstract
Colorectal cancer (CRC) is the third most common malignancy and the fourth leading cause of cancer-related death all over the world. Traditional treatments, including chemotherapy, radiation therapy, surgery and targeted therapy, form the backbone of current treatment in various stages of CRC, but the efficacy in patients with recurrent or metastatic disease is extremely poor. Recently-developed immunotherapy is frequently used in various cancers with high malignancy, such as leukemia, melanoma and non-small-cell lung cancer, and achieves promising clinical outcomes. Immunotherapy has been also investigated in CRC, but the outcome is so disappointed in majority of patients, except the PD-1 inhibitor achieved excellent result in CRC with DNA mismatch repair system deficiency. In this review, the authors will mainly introduce the immunophenotype of different subtype of CRC and summarize current advances of clinical trials for CRC immunotherapy. The article will also discuss the reasons for the low efficacy of immunotherapeutic approaches in CRC and provide several potential directions for the future development of CRC immunotherapy.关键词
结直肠癌/免疫疗法/免疫检查点抑制剂/免疫耐受/溶瘤病毒Key words
colorectal cancer/immunotherapy/immune checkpoint inhibitor/immune tolerance/oncolytic viruses分类
医药卫生引用本文复制引用
刘天池,贾为国,赵荣华,崔龙..结直肠癌免疫治疗的现状、挑战和出路[J].中国肿瘤生物治疗杂志,2018,25(10):967-978,12.基金项目
国家自然科学基金资助项目(No.81372636) （No.81372636）
